Author | David Hyman, MD | OncLive

Author | David Hyman, MD


Dr. Hyman on MEDI3617 as Potential Treatment for Patients with Advanced Solid Tumors

July 07, 2014


David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses a phase I study of the selective angiopoietin-2 inhibitor MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.